Načítá se...
Understanding how long‐acting β(2)‐adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma – an update
In moderate‐to‐severe asthma, adding an inhaled long‐acting β(2)‐adenoceptor agonist (LABA) to an inhaled corticosteroid (ICS) provides better disease control than simply increasing the dose of ICS. Acting on the glucocorticoid receptor (GR, gene NR3C1), ICSs promote anti‐inflammatory/anti‐asthma ge...
Uloženo v:
| Vydáno v: | Br J Pharmacol |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5120156/ https://ncbi.nlm.nih.gov/pubmed/27646470 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13628 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|